Top Markets
#1 GEKKO GEKKO +50.71%
#2 Helium Helium +43.66%
#3 Pons Pons +33.94%
#4 Nillion Nillion +21.92%
#5 Main Street Yield Main Street Yield +17.48%
#6 Velvet Velvet +15.44%
#7 龙虾 (Lobster) 龙虾 (Lobster) +15.09%
#8 Collect on Fanable Collect on Fanable +14.58%
#9 Cysic Cysic +14.12%
#10 o1.exchange o1.exchange +14.09%
Coin of the day
GEKKO GEKKO
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

CRVS
Rang in aandelen #8729
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Aandeelprijs
$14.07
Laatst gesynchroniseerd: 2026-08-28
Marktkapitalisatie
$1.18B
Verandering (1 dag)
-4.41%
Verandering (1 jaar)
145.13%
Land
US
Handel Corvus Pharmaceuticals, Inc. (CRVS)

Categorie

Healthcare
Dividendgeschiedenis van Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (aandelsymbool: CRVS) heeft in totaal 0 dividenduitkeringen gedaan.
De som van alle dividenden (aangepast voor aandelensplitsingen) is: 0.00
Dividendrendement (TTM): 0
Dividendbetalingen voor Corvus Pharmaceuticals, Inc. (CRVS) van 2026 tot 2026
Jaarlijkse dividendbetalingen
Jaar Dividend (aangepast voor aandelensplitsingen) Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Lijst van alle dividendbetalingen
Jaar Dividend Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendbetalingen voor vergelijkbare bedrijven of concurrenten
Bedrijf Aantal dividendbetalingen Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH